Almirall stock holds steady as 2026 earnings context stays central

Almirall (ES0157097017) stock remains tied to its latest reported operating base, with 2025 revenue at EUR 985.7 million, EBITDA at EUR 192.4 million, and reported net profit of EUR 26.1 million. The latest numbers frame the shares even without a fresh catalyst, because they set the level investors are comparing against in 2026.

2025 revenue and EBITDA

Almirall reported 2025 revenue of EUR 985.7 million, up from EUR 948.2 million in 2024, while EBITDA reached EUR 192.4 million versus EUR 180.1 million a year earlier. That means revenue increased by EUR 37.5 million year on year, and EBITDA increased by EUR 12.3 million year on year, giving the stock a concrete earnings reference point.

Net profit of EUR 26.1 million in 2025 also matters because it marked a clear improvement from the EUR 21.4 million reported in 2024. For equity holders, the margin on profit conversion is as important as the top line, especially in a healthcare group where product mix can shift the pace of earnings growth.

Profit base versus 2024

The 2025 figures show a business that expanded in both sales and profit, with revenue growth of 4.0% and EBITDA growth of 6.8% year on year. That spread suggests operating leverage, even if the headline profit pool remains relatively modest compared with revenue.

Almirall also entered 2026 with a still-visible earnings anchor from 2025 rather than a one-off balance-sheet event. That is useful for investors because the next market reaction is likely to be read against the 2025 baseline, not against a vacuum.

Which metric matters now

With 2025 revenue at EUR 985.7 million and EBITDA at EUR 192.4 million, the most relevant question for the stock is whether 2026 can extend that operating trend. The 2025 profit figure of EUR 26.1 million is not large in absolute terms, but it is a visible benchmark for any follow-through in the current year.

The comparison with 2024 is the key quantified read-through: revenue rose 4.0%, EBITDA rose 6.8%, and net profit rose 21.9%. Those are the numbers that matter when the market starts to price the next reporting step.

Product focus

For a company like Almirall, the product mix matters because dermatology-driven revenue tends to depend on both prescription momentum and commercial execution. The annual figures show that the business was able to lift both turnover and EBITDA in 2025, which keeps attention on whether that mix can be repeated into 2026.

Stock level to watch

Without a verified live quote in the available data, the cleanest market reference is the 2025 earnings base itself: revenue of EUR 985.7 million, EBITDA of EUR 192.4 million, and net profit of EUR 26.1 million as the backdrop for the shares. That combination gives Almirall stock a dated valuation and operating anchor as the next market session unfolds.